SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its revenue and gross-margin outlook on stronger AI-platform demand, driving a major after-hours rally. Many traders welcomed the improved outlook and anticipated further gains or short covering, while others questioned whether the momentum would hold given the companys volatile history and lingering trust concerns.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results beat expectations, with rapid growth in its AI compute business and an aggressive buildout outlook driving strong enthusiasm. Traders are also debating whether the ambitious growth targets justify the valuation given heavy capital spending and uncertain execution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly profit beat expectations, but softer forward guidance and a reduced advertising-revenue outlook have intensified concerns about slowing growth and weighed on the shares. Traders are debating whether the ad business and content strategy can revive momentum, with many bearish while some view the selloff as overdone and are buying the dip.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A sharp, high-volume rebound has put WULF in focus, with traders crediting CEO Paul Pragers CNBC interview and his explanation of the companys powered-shell model: leasing data-center infrastructure and power rather than buying GPUs. Bulls see its AI/HPC contracts and buildout as differentiating it from debt-heavy neocloud peers, while skeptics call the move a relief bounce and remain concerned about financing, execution, and the broader sector selloff.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in acute bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential beyond epilepsy. Traders are split: some view the results as validation of the pipeline, while others cite the modest placebo-adjusted benefit and higher agitation-related discontinuations as reasons for caution as the early gains faded.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention amid a price rebound and breakout chatter, with bullish traders pointing to Zebecs reported payroll, card and network adoption, including its Stellar deployment. Skeptics counter that the token has struggled to sustain gains and say adoption must translate into stronger usage, volume and token demand.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Anticipation of Reddits upcoming quarterly results is driving discussion, with traders watching for evidence that ad growth and AI data licensing can support the stock. Bulls expect strong results to break its recent range, while bears point to insider selling, valuation concerns, and frustrating price action.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Middle East shipping and infrastructure threats that raise fears of oil-supply disruptions. Bulls see the geopolitical risk premium supporting crude, while bears expect it to unwind if shipping flows normalize or peace talks progress, fueling debate over the funds volatile moves.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgicals strong Q3 earnings beat was met with a sharp selloff, as traders focused on the narrowed da Vinci procedure-growth outlook and planned pricing cuts that could pressure revenue per procedure. The community is split between calling the reaction an overdone sell-the-news move and viewing slower growth and the litigation settlement as reasons for caution.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention for outperforming the cap-weighted S&P 500 as gains spread across more constituent stocks while mega-cap technology lagged. Traders view the strength as evidence of broader participation and rotation beyond tech, though some caution that the improvement may not last.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAmgen is demonstrating strong top-line growth driven by a diverse portfolio in oncology and rare diseases...

AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026

AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026PR NewswireTHOUSAND OAKS, Calif., Oct. 20, 2026 THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen(NASDAQ:AMGN)will host a webcast call for...

AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study

AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.read more...

TEZSPIRE DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS

TEZSPIRE DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS TEZSPIRE DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITISPR NewswireTHOUSAND OAKS, Calif., Oct. 20, 2026 Symptom Improvements Versus Placebo at Week 24 Were Sustained...

Here's Why Amgen (AMGN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.45% on an annualized basis producing an average annual return of 14.3%. Currently, Amgen has a market capitalization of $230.37 billion.read more...

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Amgen (AMGN) settling at $434.03, representing a +1.86% change from its previous close.

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.

Bet on These Healthcare ETFs to Benefit From the Aging US Population

With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>No U.S. Food and Drug Administration-approved medicine currently treats persistent systemic Sjögren’s disease.&nbsp;</li><li>Amgen’s second late-stage study in patients with Sjögren’s disease is expected to finish in the fourth quarter.&nbsp;</li><li>Citi argues that the magnitude of efficacy and competitive profile of dazodalibep “remain open questions” until more “fulsome data” are presented.</li></ul><p>Shares of Amgen (AMGN) rallied as much as 5% on Tuesday after the company said its experimental autoimmune drug dazodalibep reduced disease intensity in patients with moderate-to-severe systemic Sjögren’s disease in a late-stage study.</p><p>At the time of writing, AMGN was trading 4% higher as investors reacted to Amgen’s first late-stage win for a potential systemic treatment in a disease that still has no approved disease-modifying therapy. However, Citi is awaiting more details on the study.</p><h2 class="st-heading-2">Positive Trial Results</h2><p>The OASIZ 301 trial enrolled about 621 adults with meaningful whole-body disease activity. After 48 weeks, dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems. The company said gains appeared as early as week 4 and lasted through the study.</p><p>Sjögren’s is a common autoimmune illness that attacks moisture-producing glands and can spread to joints, nerves and major organs. Patients often live with dry eyes and mouth, severe fatigue and chronic pain. No U.S. Food and Drug Administration-approved medicine currently treats persistent systemic disease.</p><p>Side effects were generally mild to moderate in the trial, Amgen said. The most common events seen more often with the drug than placebo included colds, urinary tract infections, higher blood pressure and infusion reactions. Few patients stopped treatment, and rates were similar across groups. No imbalance in blood clots or opportunistic infections was observed.</p><p>Amgen gained dazodalibep through its 2023 purchase of Horizon Therapeutics. A second late-stage study in patients with heavy symptoms but lower systemic activity is expected to finish in the fourth quarter.</p><h2 class="st-heading-2">Citi Still Wants The Full Picture</h2><p>Citi said Amgen’s dazodalibep delivered “positive” late-stage results in systemic Sjögren’s, which reduces clinical risk for “a potentially underappreciated I&amp;I (Immunology and Inflammation) asset.” However, several details that matter are absent from the topline release, so the firm argues that the magnitude of efficacy and competitive profile “remain open questions” until more “fulsome data” are presented. Citi has a Neutral rating and a $405 price target on Amgen shares, implying a potential upside of 3% from the stock’s Monday close.</p><p>Other firms developing Sjögren’s treatments include Novartis and Johnson &amp; Johnson.</p><h2 class="st-heading-2">How Did AMGN Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AMGN stock stayed in ‘bearish’ territory over the past 24 hours, while message volume remained ‘low.’</p><p><a href="https://stocktwits.com/symbol/AMGN">AMGN stock</a> has gained 25% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/twin-moves-vrtx-rises-on-kidney-disease-trial-results-maze-rallies-harder/cZMPusmRB7c">Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

The company logo and the lettering of the biotechnology company Amgen can be seen on the facade of the company's headquarters in Munich (Bavaria) on January 14, 2025. Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)

In a trial in patients with Sjögren’s disease, Amgen’s dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems.

Vanguard S&P 500 ETF

Vanguard Total Stock Market ETF

Track AMGN stock price, charts, news and real-time market activity on Stocktwits. Join the AMGN message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around AMGEN Inc stock.

AMGN Stock Price Today - AMGEN Inc. News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$438.94
Prev Close	$424.94
Open	$425.58
Dividend Yield	2.91%
50-Day Moving Average	$415.73
Beta	0.52
Avg. Volume	3.19M
PE Ratio	27.27

52-Week High	$447.03
52-Week Low	$288.00
Market Capitalization	$229.74B
EPS (Annual)	$14.23
Price to Book	20.30
Revenue Per Employee	$1.17M

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

AMGN Fundamentals